Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000921895-25-002895·BIOTECHNOLOGY VALUE FUND L P
Schedule 13G ownership disclosure
NEWCELX LTD
Common Shares, par value CHF 0.05 · CUSIP: H5835A109
Event date: 2025-10-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- BIOTECHNOLOGY VALUE FUND L P
Shares: 15,196.00 · Class: 0.3%
- BVF I GP LLC
Shares: 15,196.00 · Class: 0.3%
- BIOTECHNOLOGY VALUE FUND II LP
Shares: 11,746.00 · Class: 0.3%
- BVF II GP LLC
Shares: 11,746.00 · Class: 0.3%
- Biotechnology Value Trading Fund OS LP
Shares: 1,334.00 · Class: 0.03%
- BVF Partners OS Ltd.
Shares: 1,334.00 · Class: 0.03%
- BVF GP HOLDINGS LLC
Shares: 26,942.00 · Class: 0.6%
- BVF PARTNERS L P/IL
Shares: 28,732.00 · Class: 0.6%
- BVF INC/IL
Shares: 28,732.00 · Class: 0.6%
- LAMPERT MARK N
Shares: 28,732.00 · Class: 0.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000921895-25-002895
- Form type
- SCHEDULE 13G/A
- Filer
- BIOTECHNOLOGY VALUE FUND L P
- CIK
- CIK 918923
- Filed
- Nov 04, 2025
- Reporting period
- Oct 31, 2025
- Description
- Schedule 13G beneficial ownership